SOD1 and amyotrophic lateral sclerosis: Similarly, our results showed that Ellorarxine can significantly reduce LPS-induced IL-6 expression in Wild type SOD1 and Mutant SOD1 NSC-34 cells, which is not only consistent with previous reports of other synthetic retinoids, but also suggests that Ellorarxine may be able to successfully reduce the chronic inflammatory response observed in ALS.